

Inflammatory Syndrome in Patients on Hemodialysis

Rosa Jofré, Patrocinio Rodriguez-Benitez, Juan M. López-Gómez, and Rafael Pérez-García
Servicio de Nefrología, Hospital Gregorio Marañón, Madrid, Spain

Mortality is markedly elevated in hemodialysis (HD) patients. Between 30 and 50% of prevalent patients have elevated serum levels of inflammatory markers such as C-reactive protein and IL-6. The presence of inflammation, chronic or episodic, has been found to be associated with increased mortality risk. The causes of inflammation are multifactorial and include patient-related factors, such as underlying disease, comorbidity, oxidative stress, infections, obesity, and genetic or immunologic factors, or on the other side, HD-related factors, mainly depending on the membrane biocompatibility and dialysate quality. The adequate knowledge of these causes and their prevention or treatment if possible may contribute to improving the inflammatory state of patients who are on HD and possibly their mortality.

J Am Soc Nephrol 17: S274–S280, 2006. doi: 10.1681/ASN.2006080926

Between 30 and 50% of prevalent patients who are on hemodialysis (HD) have elevated serum levels of inflammatory markers. In some patients, this elevation is chronic, and in some, it is intermittent and generally is associated with breakthrough processes. Furthermore, on many occasions, HD sessions trigger inflammation in a way that is not always identifiable with the conventional markers. Inflammatory markers are powerful predictors of mortality after adjustment for other risk factors (1–7). Inflammation also is responsible for other mortality risk factors, such as anemia, malnutrition, vascular disease, and left ventricular hypertrophy. For lowering the high morbidity/mortality rate in patients who are on HD, inflammation must be tackled. How? First, by identifying the causes, then preventing or treating them. This review examines the causes of inflammation in HD (Table 1) and how to approach them.

Inflammatory Markers

The gold standard among the microinflammatory markers in HD is C-reactive protein (CRP) (1–5). It is easy to measure and a good predictor of short-term (1 to 2 yr) mortality and has become a routine test in HD units to warn of inflammation. IL-6 probably is more related to mortality and is associated with more causes of inflammation than CRP (6,7); however, it is more difficult to measure, and it is of little use in clinical practice. All acute-phase reactants are inflammation markers. At the present, new markers that are more sensitive to specific situations are being sought, such as procalcitonin (8).

Underlying Disease and Comorbidity

Underlying disease *per se* can result in a chronic inflammatory state, as in the cases of autoimmune diseases and amyloidosis. Moreover, comorbidity, mainly as a result of ischemic cardiopathy, peripheral vascular disease, or diabetes, can be a risk factor for inflammation and oxidative stress (9,10).

Oxidative Stress

Among the nonconventional cardiovascular risk factors, oxidative stress and vascular calcification gradually are gaining importance. Glycoxidation products and advanced oxidation protein products show a close relationship with inflammatory markers such as CRP and IL-6 (11–13). Therefore, the end products of these processes could act as inflammatory markers.

The generalized use of intravenous iron to treat anemia in HD units is noteworthy. Intravenous iron administration may release free iron that could react with hydrogen peroxide and generate free radicals. This results in an increase in advanced oxidation protein product levels, which are related to CRP levels (14), and in common carotid artery intima-media thickness (15). Therefore, treatment with intravenous iron could be considered as an additional inflammatory factor, as well as a risk factor for atherosclerosis in HD patients.

Vascular Calcification

Vascular calcification is more frequent and more severe in HD patients than in the general population. Both artery intimal and artery medial calcifications occur and constitute a significant morbidity/mortality marker that is associated with coronary atherosclerosis and arterial stiffness. Its cause is multifactorial. On the one hand, mineral metabolism alterations plays an important role, especially when there is an increase in serum phosphate or calcium-phosphorus product (16,17). On the other hand, there are certain vascular calcification inhibitors, such as fetuin-A and matrix Gla protein, that are inversely correlated with inflammation markers (18–20) and with coronary calcifications (21).

Infections

Several studies have demonstrated that infection by some microorganisms may participate in the development of inflammation and vascular damage in the general population (22–24). Infection with *Chlamydia pneumoniae* or *Helicobacter pylori* and periodontal disease are the most frequent. In HD patients, the presence of IgG or IgA antibodies to *C. pneumoniae* is associated

Address correspondence to: Dr. Juan M. López Gómez, Dialysis Unit, Hospital Gregorio Marañón, Dr. Esquerdo 46, 28007 Madrid, Spain. Phone: +34-91-426-5140; Fax: +34-91-586-8315; E-mail: juanmlopez@senefro.org

Table 1. Causes of inflammation in HD^a

Patient related
underlying disease
comorbidity, peripheral vascular disease
oxidative stress
Ca × P metabolism (calcification, fetuin-A)
infection (apparent and non-apparent)
<i>Helicobacter pylori</i>
<i>Chlamydia pneumoniae</i>
periodontitis
tuberculosis and others
vascular access
immunologic
genetic
nonfunctioning kidney transplants
encapsulating peritoneal sclerosis
anemia (hepcidin)
heart failure
obesity
tumors
physical exercise: sedentary lifestyle
Dialysis technique related
retention of inflammatory mediators
oxidative imbalance
acetate
pyrogenic substances of the dialysate
complement activation; membranes and other
bioincompatible material

^aHD, hemodialysis.

with a greater risk for cardiovascular events, and mortality is significantly higher (25,26). Furthermore, the carotid artery intima-media thickness has been reported to be greater in patients with IgA antibodies compared with patients without antibodies (27), and the number of atherosclerotic plaques is related to the titer of IgG antibodies in smokers but there is no such relationship in nonsmokers (28). In contrast, other authors found no differences in atherosclerosis scores between patients with and without antibodies (29), and the association with atherosclerotic disease was found to be very weak (30). Therefore, the relationship between infection with *C. pneumoniae* and atherosclerosis has not been established clearly. There is no clear connection between inflammation and *H. pylori* infection in HD patients either, as recently demonstrated (30). Consequently, further studies to establish the possible relationship between these infections and atherosclerosis are needed.

Periodontal disease is frequent in HD patients and is related to age, diabetes, smoking, HD duration, malnutrition, and inflammation (31). IgG antibodies to some periodontal bacilli are related to higher CRP levels (32). Moreover, CRP levels and erythrocyte sedimentation rate significantly decrease after periodontal treatment (33). Periodontitis, therefore, is a frequent occult source of chronic inflammation that could contribute to the atherosclerosis process and resistance to erythropoietic agents.

The prevalence of tuberculosis, mainly extrapulmonary, is increased among dialysis patients as a consequence of the depression of cellular immunity (34). Although the relationship with the inflammatory state has not been evaluated yet, it probably can be a contributory factor.

The type of HD vascular access is of prime importance for the evolution of HD patients. Patients with an indwelling catheter have higher comorbidity and a poorer survival on HD (35). However, its relationship with the inflammatory state has not been assessed sufficiently. It was demonstrated recently that patients with an indwelling tunnelled catheter have higher CRP levels and greater resistance to erythropoietin than those with arteriovenous grafts (AVG) or an arteriovenous fistula, who have the lowest values (36). Furthermore, patients with clotted AVG have elevated CRP, advanced glycation end products, and endothelial adhesion molecule levels (37–39). This demonstrates that clotted vascular access may play an important role in the inflammatory process. The elimination of these clotted grafts may result in a significant improvement in inflammation parameters (37). These findings suggest the need to monitor inflammation markers in patients with old clotted AVG, so they must be removed when in doubt.

Genetic and Immunologic Factors

Genetic factors such as single-nucleotide polymorphisms may influence significantly the immune response, the levels of inflammatory markers, and body composition, as well as the prevalence of vascular calcification in patients with chronic renal failure. Although genetic variations in the TNF- α -308 and IL-10-1082 single-nucleotide polymorphisms seem to be associated consistently with adverse clinical outcome in patients with ESRD, the results regarding genetic variations in the IL-6 gene have been conflicting (40).

Returning to HD after kidney transplant failure is becoming more frequent, especially in countries with high transplantation rates. It is standard practice to leave the nonfunctioning kidney transplant in place, even with low dosages of immunosuppressors, to maintain a minimum residual function. However, recent studies have demonstrated that, at least in some cases, the nonfunctioning kidney graft could act as a potent mediator of inflammation and erythropoietin resistance. In some cases, this situation may be completely asymptomatic but with the only evidence of elevated inflammatory markers. Only surgical removal of the graft can reverse the inflammatory state in these patients (41).

Encapsulating Peritoneal Sclerosis

This is a rare complication in peritoneal dialysis patients, and it means that they have to be placed on HD. These patients have elevated levels of biochemical inflammatory markers and a very poor prognosis (42). The best treatment is prophylaxis, with early detection of the disease in the peritoneal effluent in high-solute transporters. This disease currently is treated with pentoxifylline or tamoxifen with encouraging results (43,44).

Anemia

Although relative erythropoietin deficiency is a major factor in the anemia that is associated with chronic kidney disease, the chronic inflammatory state of uremic patients is an important associated factor. Stimulated mononuclear cells release numerous inflammatory cytokines such as IL-1, IL-6, TNF- α , and IFN- γ that may contribute to erythropoiesis suppression. Although the exact mechanism for this effect is not yet clear, the induction of apoptosis in erythroid progenitor cells is an important factor (45). Then, anemia mainly is a consequence of the inflammatory state instead of a cause. However, in recent years, hepcidin has been implicated as a complementary mechanism. This antimicrobial peptide, synthesized in the liver, inhibits intestinal iron absorption and is released into the circulation from the macrophages. It is stimulated by iron overload, hypoxia, and inflammation. The transcription of hepcidin is induced by IL-6 (46,47). In view of all this, hepcidin may be the link between inflammation and anemia (48,49), acting as an indicator of functional iron deficiency (50).

Heart Failure

Patients who are on HD and have a history of heart failure may have higher CRP levels (51). Furthermore, left ventricular hypertrophy has been associated with chronic inflammation states and oxidative stress (50,52–54). Recent studies have demonstrated that high-sensitivity CRP levels correlate positively with left ventricle mass and negatively with ejection fraction, and the multivariate analysis revealed that the chronic inflammatory state may be considered an independent risk factor for the development of cardiac hypertrophy and ventricular dysfunction in HD patients (52). However, whether control of the inflammatory state is accompanied by an improvement in cardiac size and function is not so clear.

Obesity

Obesity is part of the inverse epidemiology described for HD patients. In contrast to what occurs in the general population, HD patients with lower body mass index have a greater risk for mortality (55,56), and patients with excess weight have improved survival (57,58). Loss of adipose tissue may be the result of an inflammatory state, in which the release of proinflammatory cytokines may give rise to anorexia, predisposition to malnutrition, and weight loss (59–61). However, adipocytes are an important source of proinflammatory cytokines such as IL-6 and TNF- α , usually produced by monocytes, but they also are capable of producing other, more specific proteins, such as leptin and adiponectin. The latter is produced in a larger quantity than leptin and is inversely related with body mass index and resistance to insulin. Therefore, low adiponectin levels are associated with inflammatory markers and act as a predictor of cardiovascular events and mortality (61,62).

HD Technique

HD technique may contribute to maintaining the inflammatory state in many HD patients. Several theoretical mechanisms may be implicated: (1) The retention or nonelimination of proinflammatory molecules usually eliminated by the kidney;

(2) potentiation of oxidative stress; and (3) stimulation of antigen-presenting cells, mainly monocytes, either directly or through contaminants. These cells in HD patients usually are preactivated, expressing CD-14 and CD-16 phenotypes in a greater proportion than in the general population (63).

Among the molecules that may be eliminated by convective transport using hemodiafiltration techniques are complement components (64), asymmetric dimethylarginine (65), and cytokines (66). It would be through this mechanism, by elimination of proinflammatory substances, that the preservation of renal function correlates inversely with inflammatory markers (67). HD regimens with greater deuration of all kinds of substances, such as nocturnal HD, also would have this effect (68). Techniques with a high middle molecule clearance, such as on-line hemodiafiltration, may contribute to decreasing inflammation in HD patients. Some protein-leaking dialyzers can improve chronic inflammation in HD patients (69).

Oxidative stress forms part of the inflammation mechanism. HD often is associated with an oxidative imbalance, in which oxidation of different lipids and proteins are predominant (68). Loss of some antioxidants, such as carnitine, during HD may contribute to this disorder (70). There is a clear interconnection between inflammation and oxidative stress in HD (71,72).

Several current HD components may provoke inflammation in patients. There is an intermittent, multiple stimulation during each HD session. Among these components are acetate, pyrogenic substances, and activation of the complement mainly as a result of dialysis membranes.

Exposure to 2 to 4 mmol/L acetate, which is contained in the bicarbonate dialysate, produces in many patients pathologic increases in acetatemia that could initiate inflammation or intolerance to the dialysis technique (73–75). Techniques such as acetate-free biofiltration or acetate-free dialysate could prevent this increase (74,75).

It has been demonstrated that pyrogenic substances are transferred to the blood through the dialysis membrane (Table 2). This depends not only on the amount of pyrogenic substances but also on its quality, and although this transfer occurs mainly by backfiltration (76), low molecular weight substances also may enter by backdiffusion. Endotoxins can cross any type of HD membrane; however, it has been reported that this occurs more easily with highly permeable membranes, in which backfiltration is more common. Reactions to pyrogens are much more frequent with high-permeability membranes than with low-permeability ones (77). Dialysis membranes that are capable of absorbing/retaining endotoxins, such as polysulfone, polyamide, polysidine, and polyethersulfone, may decrease endotoxin transfer (78). Once in the blood, endotoxins are capable of activating monocytes and inducing cytokine release (79). This monocyte activation is not linear, and several factors intervene to increase or decrease cytokine production. It is a multifactorial process that is influenced by the type and the level of toxin, the type of membrane, various plasma factors, and the concomitant action of other monocyte activation and inactivation systems (79). It is known that the presence of proteins or whole blood is a potentiating factor in this activation process. Currently, at least two proteins are known: LPS-

Table 2. Bacterium-derived pyrogens and their detection

Bacterium Cell Wall	Molecular Weight (Da)	Limulus Test	Mononuclear Cell Test
Components			
LPS	>100,000	+	+
lipid A	2000 to 4000	+	+
other LPS fragments	<8000	+/-	+
peptidoglycans	1000 to 20,000	-	+
muramylpeptides	400 to 1000	-	+
others		-	+
Other cellular components			
bacteria DNA	Variable	-	+
Secreted toxins			
exotoxin A	71,000	-	+
exotoxin A fragment	<1000	-	+
other exotoxins	20,000 to 50,000	-	+

binding protein, a transporter, and a bactericidal permeability-increasing protein. These two proteins are necessary for this process to be carried out (80). The concomitant presence of other stimuli or signs, such as the activation of the complement, is very important. Finally, to make this process even more complex, some cytokine downregulators come into play, such as IL-10 (81). All of the above emphasizes the importance of the patient's nutritional and immune system status in this field and explains the different patient responses to the same HD technique.

The dialysis membrane and its capacity to stimulate monocytes, either directly or through activation of the complement, increasing cytokine production, is another specific inflammatory factor in HD patients. The behavior of HD membranes varies greatly, and some of them clearly are more biocompatible than others.

Monocytes, as effector cells, respond to the various stimuli and produce a chronic release of cytokines. Knowing that monocytes express the endotoxin receptor antigen CD14 (82) confirms that endotoxins are their primary stimuli. Nevertheless, for cytokines to be secreted, other concomitant stimuli are needed, such as the complement CD16 (82).

To prevent this inflammatory state, several actions must be taken: prevent and treat bacteria contamination of the dialysate; eliminate endotoxins from the dialysate by using suitable filters in the HD equipment hydraulic circuit; prevent or treat chronic infections in HD patients; use ultrapure dialysate; use biocompatible materials to prevent concomitant stimuli of the monocytes; and eliminate acetate, even low levels, in the dialysate. Maintaining a good nutritional status in HD patients may contribute to an improved immune response. Acting on LPS-binding protein and bactericidal permeability-increasing protein or on monocyte or cytokine receptors still is in the preliminary stages. The elimination of some of these stimuli could decrease the inflammatory response in patients who are on HD and are identified by plasma levels of inflammatory markers (8).

Conclusion

HD patients with inflammation have a poorer prognosis. Biochemical inflammatory markers help us to identify these patients. In most cases, the cause of inflammation can be determined through clinical investigation, and some of them may be eliminated or corrected. The prevention and the treatment of inflammatory syndrome is of high priority in patients who are on HD.

References

- Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis. *Kidney Int* 55: 648–658, 1999
- Barany P, Divino JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. *Am J Kidney Dis* 29: 565–568, 1997
- Haverkate F, Thompson SG, Pye SDM, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. *Lancet* 349: 462–466, 1997
- Bergstrom J, Heimbürger O, Lindholm B, Qureshi AR: C-reactive protein as predictor for serum albumin and mortality in hemodialysis. *J Am Soc Nephrol* 6: 573–577, 1995
- Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis* 35: 469–476, 2000
- Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in dialytic patients. *Nephrol Dial Transplant* 19: 1154–1160, 2004
- Pecoits-Filho R, Barany P, Lindholm B, Heimbürger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. *Nephrol Dial Transplant* 17: 1684–1688, 2002
- Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, Men-

- gozzi G, Santoro A, Coppo R: Procalcitonin as a marker of micro-inflammation in hemodialysis. *J Nephrol* 18: 282–288, 2005
9. Vaziri ND: Oxidative stress in uremia: Nature, mechanisms, and potential consequences. *Semin Nephrol* 24: 469–473, 2004
 10. Jaar BG, Hermann JA, Furth SL, Briggs W, Powe NR: Septicemia in diabetic hemodialysis patients: Comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. *Am J Kidney Dis* 35: 282–292, 2000
 11. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. *Am J Kidney Dis* 38: 1408–1413, 2001
 12. Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan IM, Spacek P, Braun M, Mikulikova L, Fortova M, Horejsi M, Tesar V, Zima T: Glycooxidation and inflammation in chronic haemodialysis patients. *Nephrol Dial Transplant* 18: 2577–2581, 2003
 13. Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, Himmelfarb J: Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. *Am J Kidney Dis* 42: 286–294, 2003
 14. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. *Am J Kidney Dis* 40: 1005–1012, 2002
 15. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. *Circulation* 22: 2212–2217, 2002
 16. Ishimura E, Taniwaki H, Tabata T, Tsujimoto Y, Jono S, Emoto M, Shoji T, Inaba M, Inoue T, Nishizawa Y: Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. *Am J Kidney Dis* 45: 859–865, 2005
 17. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol* 16: 520–528, 2005
 18. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahn-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. *Lancet* 8: 827–833, 2003
 19. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L: Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int* 67: 2383–2392, 2005
 20. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis* 47: 139–148, 2006
 21. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahn-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). *Kidney Int* 67: 2295–2304, 2005
 22. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ *et al.*: Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections with coronary heart disease and cardiovascular risk factors. *BMJ* 311: 711–714, 1995
 23. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Manttari M, Frick MH, Huttunen JK: Chronic *Chlamydia pneumoniae* infection as a risk factor for coronary heart disease in the Helsinki Heart Study. *Ann Intern Med* 116: 273–278, 1992
 24. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, Sweetnam PM, Elwood PC: Relation of *Chlamydia pneumoniae* serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. *BMJ* 318: 1035–1040, 1999
 25. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F, Timio M: Inflammation, infection and cardiovascular events in chronic hemodialysis patients: A prospective study. *J Nephrol* 16: 245–251, 2003
 26. Zoccali C, Mallamaci F, Tripepi G: Atherosclerosis in dialysis patients: Does *Chlamydia pneumoniae* infection contribute to cardiovascular damage? *Nephrol Dial Transplant* 17[Suppl 8]: 25–28, 2002
 27. Kato A, Takita T, Maruyama Y, Hishida A: Chlamydial infection and progression of carotid atherosclerosis in patients on regular haemodialysis. *Nephrol Dial Transplant* 19: 2539–2546, 2004
 28. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. *J Hypertens* 18: 1207–1213, 2000
 29. Tsirpanlis G, Chatzipanagiotou S, Ioannidis A, Moutafis S, Pouloupoulou C, Nicolaou C: Detection of *Chlamydia pneumoniae* in peripheral blood mononuclear cells: Correlation with inflammation and atherosclerosis in haemodialysis patients. *Nephrol Dial Transplant* 18: 918–923, 2003
 30. Lentine KL, Parsonnet J, Taylor I, Wrone EM, Lafayette RA: Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. *Clin Exp Nephrol* 10: 55–62, 2006
 31. Chen LP, Chiang CK, Chan CP, Hung KY, Huang CS: Does periodontitis reflect inflammation and malnutrition status in hemodialysis patients? *Am J Kidney Dis* 47: 815–822, 2006
 32. Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW: Serum markers of periodontal disease status and inflammation in hemodialysis patients. *Am J Kidney Dis* 40: 983–989, 2002
 33. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME: Periodontitis is an important and occult source of inflammation in hemodialysis patients. *Blood Purif* 24: 400–404, 2006
 34. Hussein MM, Mooij JM, Roujouleh H: Tuberculosis and chronic renal disease. *Semin Dial* 16: 38–44, 2003
 35. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ: Effect of change in vascular access on patient mortality in hemodialysis patients. *Am J Kidney Dis* 47: 469–477, 2006
 36. Movilli E, Brunori G, Camerini C, Vizzardì V, Gaggia P,

- Cassamali S, Scolari F, Cancarini GC: The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. *Blood Purif* 24: 387–393, 2006
37. Nassar GM, Fishbane S, Ayus JC: Occult infection of old nonfunctioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. *Kidney Int* 80: 49–54, 2002
 38. Cai W, Zhu L, Chen X, Uribarri J, Peppia M: Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients. *Am J Nephrol* 26: 181–185, 2006
 39. Chang CJ, Ko YS, Ko PJ, Hsu LA, Chen CF, Yang CW, Hsu TS, Pang JH: Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. *Kidney Int* 68: 1312–1319, 2005
 40. Stenvinkel P, Pecoits-Filho R, Lindholm B; for the DialGene Consortium: Gene polymorphism association studies in dialysis: The nutrition-inflammation axis. *Semin Dial* 18: 322–330, 2005
 41. Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Benitez P, Villaverde M, Perez-Garcia R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. *J Am Soc Nephrol* 15: 2494–2501, 2004
 42. Garosi G, Di Paolo N: Inflammation and gross vascular alterations are characteristic histological features of sclerosing peritonitis. *Perit Dial Int* 21: 417–418, 2001
 43. Eltoun MA, Wright S, Atchley J, Mason JC: Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. *Perit Dial Int* 26: 203–206, 2006
 44. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ: Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: Implications for prevention of encapsulating peritoneal sclerosis. *Nephrol Dial Transplant* 18: 670–676, 2003
 45. Macdougall IC, Cooper AC: Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. *Eur J Clin Invest* 35[Suppl 3]: 32–35, 2005
 46. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hpcidin, a new iron regulatory peptide. *Blood Cells Mol Dis* 29: 327–335, 2002
 47. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hpcidin transcription by interleukin-1 and interleukin 6. *Proc Natl Acad Sci U S A* 102: 1906–1910, 2005
 48. Andrews NC: Anemia of inflammation: The cytokine-hepcidin link. *J Clin Invest* 113: 1251–1253, 2004
 49. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC: Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. *Blood* 100: 3776–3781, 2002
 50. Park CW, Shin YS, Kim CM, Lee SY, Yu SE, Kim SY, Choi EJ, Chang YS, Bang BK: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. *Am J Kidney Dis* 40: 1230–1239, 2002
 51. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J: Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? *J Am Soc Nephrol* 14: 1871–1879, 2003
 52. Losito A, Kalidas K, Santoni S, Jeffery S: Association of interleukin-6–174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. *Kidney Int* 64: 616–622, 2003
 53. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Druke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. *Nephrol Dial Transplant* 16: 335–340, 2001
 54. Kim BS, Jeon DS, Shin MJ, Kim YO, Song HC, Lee SH, Kim SY, Choi EJ, Chang YS, Bang BK: Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. *Am J Nephrol* 25: 189–195, 2005
 55. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. *Kidney Int* 58: 900–906, 2000
 56. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. *J Am Soc Nephrol* 13: 1061–1066, 2002
 57. Kopple JD: Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr* 83: 202–210, 2006
 58. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 16: 2386–2394, 2001
 59. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? *Kidney Int* 62: 1791–1798, 2002
 60. Kaizu Y, Tsunega Y, Yoneyama T, Sakao T, Hibi I, Miyaji K, Kumagai H: Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. *Clin Nephrol* 50: 44–50, 1998
 61. Zoccali C, Mallamaci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. *Nephrol Dial Transplant* 19[Suppl 5]: S67–S72, 2004
 62. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney Int* 65: 274–281, 2004
 63. Ramirez R, Carracedo J, Berdud I, Carretero D, Merino A, Rodriguez M, Tetta C, Martin-Malo A, Aljama P: Microinflammation in hemodialysis is related to a preactivated subset of monocytes. *Hemodial Int* 10[Suppl 1]: S24–S27, 2006
 64. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. *Kidney Int Suppl* 78: S271–S277, 2001
 65. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. *J Am Soc Nephrol* 13: 170–176, 2002

66. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson E: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. *J Am Soc Nephrol* 15: 2186–2194, 2004
67. Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM: Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. *J Am Soc Nephrol* 14: 2322–2328, 2003
68. De los Reyes B, Navarro JA, Perez-Garcia R, Liras A, Campos Y, Bornstein B, Arenas J: Effects of L-carnitine on erythrocyte acyl-CoA, free CoA and glycerophospholipid acyltransferase in uremia. *Am J Clin Nutr* 67: 386–390, 1998
69. Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U: Glycosylation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. *Kidney Int* 67: 750–759, 2005
70. Lago M, Perez Garcia R, Arenas J, De los Reyes B, Anaya F, Garcia de Vinuesa MS, Dall'Anese C, Valderrabano F: Carnitine losses in hemodialysis: Influence of different dialyzers and its relationship with nutritional status. *Nefrologia* 15: 55–61, 1995
71. De Leo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP: Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. *J Clin Invest* 101: 455–463, 1998
72. Morena M, Cristol JP, Canaud B: Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. *Blood Purif* 18: 191–199, 2000
73. Amore A, Coppo R: Acetate intolerance and synthesis of nitric oxide by endothelial cells. *J Am Soc Nephrol* 8: 1431–1436, 1997
74. Coll E, Perez-Garcia R, Rodriguez-Benitez P, Ortega M, Martinez P, Jofre R, Lopez-Gomez JM: Hemodialysis without acetic acid: Clinical and analytical changes [Abstract]. *J Am Soc Nephrol* 16: 442A, 2005
75. Amore A, Cirina P, Bonaudo R, Conti G, Chiesa M, Coppo R: Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. *J Nephrol* 19: 57–64, 2006
76. Panichi V, Migliori M, De Pietro S, Metelli MR, Taccola D, Perez Garcia R, Palla R, Rindi P, Cristofani R, Tetta C: Plasma C-reactive protein in hemodialysis patients: A cross-sectional, longitudinal clinical survey. *Blood Purif* 18: 30–36, 2000
77. Perez-Garcia R, Anaya F, Chisvert J, Valderrabano F: Association of high-flux dialyzers and bacterial contamination of dialysate induced chronic release of cytokines in haemodialysis patients. *Nephrol Dial Transplant* 11: 2164–2166, 1995
78. G. Lonnemann: Dialysate bacteriological quality and the permeability of dialyzer membranes to pyrogens. *Kidney Int* 43[Suppl 41]: 195–200, 1993
79. Pertosa G, Gesualdo L, Bottalico D, Schena FP: Endotoxins modulate chronically tumour necrosis factor alpha and interleukin 6 release by uraemic monocytes. *Nephrol Dial Transplant* 10: 328–333, 1995
80. Sundaram S, King AJ, Pereira BJ: Lipopolysaccharide-binding protein and bactericidal/permeability-increasing factor during hemodialysis: Clinical determinants and role of different membranes. *J Am Soc Nephrol* 8: 463–470, 1997
81. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Buschenfelde KHM, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. *Kidney Int* 47: 559–565, 1995
82. Scherberich JE, Nockher WA: Blood monocyte phenotypes and soluble endotoxin receptor CD14 in systemic inflammatory diseases and patients with chronic renal failure. *Nephrol Dial Transplant* 15: 574–577, 2000